Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders

Current Pharmaceutical Design

Volumn 21, Issue 23, 2015, Pages 3352-3358

  Geoffroy, Pierre Alexis ^a,b,c,d   Etain, Bruno ^d,e,f,g   Micoulaud Franchi, Jean Arthur ^h,i   Bellivier, Frank ^a,b,c,d   Ritter, Philipp ^j  

^a UMR S 1144   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d FONDATION FONDAMENTAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f INSERM U955   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

more..

Author keywords

Bipolar disorders; Circadian rhythms; Melatonin; Ramelteon; Sleep; Tasimelteon

Indexed keywords

MELATONIN; MOOD STABILIZER; RAMELTEON; TASIMELTEON; BENZOFURAN DERIVATIVE; CYCLOPROPANE DERIVATIVE; INDENE DERIVATIVE; MELATONIN RECEPTOR; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INSOMNIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SLEEP DISORDER; SLEEP QUALITY; AGONISTS; CIRCADIAN RHYTHM; CLINICAL PRACTICE; DRUG EFFECTS; INAPPROPRIATE PRESCRIBING; METABOLISM; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PATIENT SAFETY; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; SLEEP; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZOFURANS; BIPOLAR DISORDER; CIRCADIAN RHYTHM; CYCLOPROPANES; HUMANS; INAPPROPRIATE PRESCRIBING; INDENES; MELATONIN; OFF-LABEL USE; PATIENT SAFETY; PRACTICE PATTERNS, PHYSICIANS'; RECEPTORS, MELATONIN; RISK ASSESSMENT; RISK FACTORS; SLEEP; TREATMENT OUTCOME;

EID: 84938614110     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150619093448     Document Type: Article

References (80)

1. [1] Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64(5): 543-52.
2. [2] Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011; 475(7354): 27-30.
3. [3] Geoffroy PA, Etain B, Jamain S, Bellivier F, Leboyer M. Early onset bipolar disorder: validation from admixture analyses and biomarkers. Can J Psychiatry 2013; 58(4): 240-8.
4. [4] Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382(9904): 1575-86.
5. [5] Lichtenstein P, Yip BH, Björk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009; 373(9659): 234-9.
6. [6] Etain B, Milhiet V, Bellivier F, Leboyer M. Genetics of circadian rhythms and mood spectrum disorders. Eur Neuropsychopharmacol 2011; 21 (Suppl 4): S676-82.
7. [7] Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008; 165(7): 820-9.
8. [8] McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007; 114(2): 222-32.
9. [9] Geoffroy PA, Scott J, Boudebesse C, et al. Sleep in patients with remitted bipolar disorders: a meta-analysis of actigraphy studies. Acta Psychiatr Scand 2015; 131(2): 89-99.
10. [10] Rocha PMB, Neves FS, Correa H. Significant sleep disturbances in euthymic bipolar patients. Compr Psychiatry 2013; 54(7): 1003-8.
11. [11] Harvey AG, Schmidt DA, Scarnä A, Semler CN, Goodwin GM. Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems. Am J Psychiatry 2005; 162(1): 50-7.
12. [12] Boudebesse C, Lajnef M, Geoffroy PA, et al. Chronotypes of bipolar patients in remission: validation of the French version of the cir- circadian type inventory in the FACE-BD sample. Chronobiol Int 2013; 30(8): 1042-9.
13. [13] Robillard R, Naismith SL, Rogers NL, et al. Delayed sleep phase in young people with unipolar or bipolar affective disorders. J Affective Disorders 2013; 145(2): 260-3.
14. [14] Geoffroy PA, Scott J, Boudebesse C, et al. Sleep in patients with remitted bipolar disorders: analyses stratified on actigraphy devices, age and gender. Acta Psychiatr Scand 2015; 131(2): 89-99.
15. [15] Sylvia LG, Dupuy JM, Ostacher MJ, et al. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol (Oxford) 2012; 26(8): 1108-12.
16. [16] Kaplan KA, Gruber J, Eidelman P, Talbot LS, Harvey AG. Hypersomnia in inter-episode bipolar disorder: does it have prognostic significance? J Affect Disord 2011; 132(3): 438-44.
17. [17] Jackson A, Cavanagh J, Scott J. A systematic review of manic and depressive prodromes. J Affect Disord 2003; 74(3): 209-17.
18. [18] Geoffroy PA, Etain B, Sportiche S, Bellivier F. Circadian biomarkers in patients with bipolar disorder: promising putative predictors of lithium response. Int J Bipolar Disorders 2014; 2(1): 5.
19. [19] Scott J. Clinical parameters of circadian rhythms in affective disorders. Eur Neuropsychopharmacol 2011; 21 Suppl 4: S671-5.
20. [20] Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9(1): 11-24.
21. [21] Hickman AB, Klein DC, Dyda F. Melatonin biosynthesis: the structure of serotonin N-acetyltransferase at 2.5 A resolution suggests a catalytic mechanism. Mol Cell 1999; 3(1): 23-32.
22. [22] Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A metaanalysis. J Gen Intern Med 2005; 20(12): 1151-8.
23. [23] Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013; 8(5): e63773.
24. [24] Van Geijlswijk IM, Korzilius HPLM, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010; 33(12): 1605-14.
25. [25] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53(9): 783-92.
26. [26] Doyen C, Mighiu D, Kaye K, et al. Melatonin in children with autistic spectrum disorders: recent and practical data. Eur Child Adolesc Psychiatry 2011; 20(5): 231-9.
27. [27] Cortesi F, Giannotti F, Ivanenko A, Johnson K. Sleep in children with autistic spectrum disorder. Sleep Med 2010; 11(7): 659-64.
28. [28] Stahl SM. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr 2014; 19(3): 207-12.
29. [29] Nurnberger JI Jr, Adkins S, Lahiri DK, et al. Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry 2000; 57(6): 572-9.
30. [30] Nurnberger JI Jr, Berrettini W, Tamarkin L, Hamovit J, Norton J, Gershon E. Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder. A preliminary report. Neuropsychopharmacology 1988; 1(3): 217-23.
31. [31] Kennedy SH, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res 1996; 63(2-3): 219-22.
32. [32] McIntyre IM, Norman TR, Burrows GD, Armstrong SM. Human melatonin suppression by light is intensity dependent. J Pineal Res 1989; 6(2): 149-56.
33. [33] Hallam KT, Olver JS, Chambers V, Begg DP, McGrath C, Norman TR. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 2006; 31(7): 867-75.
34. [34] Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 2001; 22(1): 18-32.
35. [35] Lam RW, Berkowitz AL, Berga SL, Clark CM, Kripke DF, Gillin JC. Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res 1990; 33(2): 129-34.
36. [36] Whalley LJ, Perini T, Shering A, Bennie J. Melatonin response to bright light in recovered, drug-free, bipolar patients. Psychiatry Res 1991; 38(1): 13-9.
37. [37] Rubin RT, Heist EK, McGeoy SS, Hanada K, Lesser IM. Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch Gen Psychiatry 1992; 49(7): 558-67.
38. [38] Nováková M, Pra_ko J, Látalová K, Sládek M, Sumová A. The circadian system of patients with bipolar disorder differs in episodes of mania and depression. Bipolar Disord 2015; 17(3): 303-14.
39. [39] Kennedy SH, Tighe S, McVey G, Brown GM. Melatonin and cortisol « switches » during mania, depression, and euthymia in a drugfree bipolar patient. J Nerv Ment Dis 1989; 177(5): 300-3.
40. [40] Li S-X, Liu L-J, Xu L-Z, et al. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology 2013; 38(11): 2789-99.
41. [41] Sarrazin S, Etain B, Vederine F-E, et al. MRI exploration of pineal volume in bipolar disorder. J Affect Disord 2011; 135(1-3): 377-9.
42. [42] Etain B, Dumaine A, Bellivier F, et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet 2012; 21(18): 4030-7.
43. [43] Geoffroy PA, Boudebesse C, Henrion A, et al. An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: a pilot study. Genes Brain Behav 2014; 13(3): 299-304.
44. [44] Bellivier F, Geoffroy P. A, Etain B, Scott J. Sleep- and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder. Expert Opin Ther Targets 2015; 1-17.
45. [45] Seggie J, Werstiuk ES, Grota L. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11(2-3): 325-34.
46. [46] Hallam KT, Olver JS, Norman TR. Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers. Neuropsychopharmacology 2005; 30(7): 1400-4.
47. [47] Hallam KT, Olver JS, Horgan JE, McGrath C, Norman TR. Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. Int J Neuropsychopharmacol 2005; 8(2): 255-9.
48. [48] Niles LP, Sathiyapalan A, Bahna S, Kang NH, Pan Y. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int J Neuropsychopharmacol 2012; 15(9): 1343-50.
49. [49] Leibenluft E, Turner EH, Feldman-Naim S, Schwartz PJ, Wehr TA, Rosenthal NE. Light therapy in patients with rapid cycling bipolar disorder: preliminary results. Psychopharmacol Bull 1995; 31(4): 705-10.
50. [50] Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62(9): 996-1004.
51. [51] Hamdani N, Tamouza R, Leboyer M. Immuno- inflammatory markers of bipolar disorder: a review of evidence. Front Biosci (Elite Ed) 2012; 4: 2170-82.
52. [52] Anderson G, Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets 2014; 13(5): 817-27.
53. [53] Milhiet V, Boudebesse C, Bellivier F, et al. Circadian abnormalities as markers of susceptibility in bipolar disorders. Front Biosci (Schol Ed) 2014; 6: 120-37.
54. [54] Takahashi JS, Hong H-K, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 2008; 9(10): 764-75.
55. [55] Kennedy JS, Gwirtsman HE, Schmidt DE, et al. Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects. Life Sci 2002; 71(14): 1703-15.
56. [56] Valevski A, Modai I, Jerushalmy Z, Kikinzon L, Weizman A. Effect of melatonin on active transport of serotonin into blood platelets. Psychiatry Res 1995; 57(2): 193-6.
57. [57] Witkovsky P. Dopamine and retinal function. Doc Ophthalmol 2004; 108(1): 17-40.
58. [58] Yocca FD, de Paul Lynch V, Friedman E. Effect of chronic lithium treatment on rat pineal rhythms: N-acetyltransferase, Nacetylserotonin and melatonin. J Pharmacol Exp Ther 1983; 226(3): 733-7.
59. [59] Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 2003; 55(2): 325-95.
60. [60] Robertson JM, Tanguay PE. Case study: the use of melatonin in a boy with refractory bipolar disorder. J Am Acad Child Adolesc Psychiatry 1997; 36(6): 822-5.
61. [61] Nierenberg AA. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother Psychosom 2009; 78(6): 391-3.
62. [62] Leibenluft E, Feldman-Naim S, Turner EH, Wehr TA, Rosenthal NE. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58(9): 383-8.
63. [63] Bersani G, Garavini A. Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(2): 185-91.
64. [64] Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord 2014; 16(4): 410-21.
65. [65] McElroy SL, Winstanley EL, Martens B, et al. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2011; 26(1): 48-53.
66. [66] Norris ER, Karen Burke null, Correll JR, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 2013; 144(1-2): 141-7.
67. [67] Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007; 30(11): 1484-501.
68. [68] Gamble KL, May RS, Besing RC, Tankersly AP, Fargason RE. Delayed sleep timing and symptoms in adults with attentiondeficit/ hyperactivity disorder: a controlled actigraphy study. Chronobiol Int 2013; 30(4): 598-606.
69. [69] Reid KJ, Jaksa AA, Eisengart JB, et al. Systematic evaluation of Axis-I DSM diagnoses in delayed sleep phase disorder and evening- type circadian preference. Sleep Med 2012; 13(9): 1171-7.
70. [70] Hansen MV, Danielsen AK, Hageman I, Rosenberg J, Gögenur I. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014; 24(11): 1719-28.
71. [71] Mostafavi A, Solhi M, Mohammadi M-R, Hamedi M, Keshavarzi M, Akhondzadeh S. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Med Iran 2014; 52(10): 734-9.
72. [72] Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140(2): 1009-12.
73. [73] Wolden-Hanson T, Mitton DR, McCants RL, et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141(2): 487-97.
74. [74] Terrón MP, Delgado-Adámez J, Pariente JA, Barriga C, Paredes SD, Rodríguez AB. Melatonin reduces body weight gain and increases nocturnal activity in male Wistar rats. Physiol Behav 2013; 118: 8-13.
75. [75] Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011; 50(3): 261-6.
76. [76] Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res 2011; 50(2): 171-82.
77. [77] Espino J, Pariente JA, Rodríguez AB. Role of melatonin on diabetes- related metabolic disorders. World J Diabetes 2011; 2(6): 82-91.
78. [78] Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 2007; 32(2): 284-8.
79. [79] Bliwise DL, Ansari FP. Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey. Sleep 2007; 30(7): 881-4.
80. [80] Anderson G. The role of melatonin in post-partum psychosis and depression associated with bipolar disorder. J Perinat Med 2010; 38(6): 585-7.